This segment focuses on the research and development of novel therapeutics for allergic and inflammatory diseases, including dermal, respiratory, and gastrointestinal conditions. Research and development activities include the identification and validation of drug targets, preclinical studies, and clinical trials. The company utilizes small molecule and gene therapy/editing programs. The goal is to develop innovative medicines that address unmet medical needs and improve patient outcomes. Market positioning is based on the development of the next wave of medicine. Future opportunities include expanding the pipeline and securing regulatory approvals. Partnerships with Novartis have been established. The company is currently in the process of liquidation.